Spintech MRI Inc. raised $6.5 million in series A financing to expand deployment of MRI software designed to improve and accelerate diagnosis and treatment of Parkinson’s disease, Alzheimer’s and other neurological diseases. The FDA-cleared Strategically Acquired Gradient Echo (Stage) platform is currently in use at more than 50 U.S. hospitals and institutions, including the Yale School of Medicine for advanced research, analysis and treatment of Parkinson’s disease.
In vitro diagnostics company Gaugene Biotechnology Ltd. has secured more than ¥100 million (US$14.8 million) in a series B financing to develop new products and technologies, as well as expand to new markets. The financing was led by Fortune Venture Capital Co. Ltd., with participation by Tao Capital, Guangdong Hybribio Biotech Co. Ltd., Qiming Venture Partners, and others.
Institut Mérieux SA is offering equity to a preferred partner via a restricted capital increase. Exor NV has consequently acquired 10% of Institut Mérieux’s capital by investing $850 million. A third of this new funding, some $285 million, will be injected immediately this summer, with the balance following over the coming 12 months.
Cleerly Inc. sees a bright future ahead after boosting its fundraising to date nearly five-fold with a $192 million series C. The new infusion brought the total invested in the company to $248 million, a solid endorsement of a company that hopes to transform cardiology with precision-based diagnostics that move away from indirect indicators to accurate measurements.
Forsight Robotics Ltd. amassed up to $55 million in series A financing led by Adani Group, with participation by existing investors Eclipse Ventures and Mithril Capital. The new funds will be used to further development of Forsight’s Oryom system, a surgical platform for fully robotic cataract surgery.
RSS
